The company operates in a single business segment: human pharmaceutical products. An array of pharmaceutical pills with the ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Threats: Intense competition and patent expirations leading to generic competition.

Eli Lilly executives insisted that underlying demand for the medicines remained strong and that the company has enough supply ...

He noted that Lilly “is just getting started in commercializing obesity products globally ... twice what the company registered for 2023. Shares of Indianapolis-based Eli Lilly and Co ...

Here's why Eli Lilly ... my eyes on the company's oral obesity drug orforglipron, which is currently in phase 2 testing.

Sales of Eli Lilly’s diabetes and weight loss drugs fell far short of expectations in the third quarter, leading the juggernaut company to reduce its annual revenue guidance and triggering speculation ...

Lilly (NYSE: LLY) makes drugs including Mounjaro for type 2 diabetes and Zepbound for obesity. For 2023, it reported $34 ...

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...